These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.


BIOMARKERS

Molecular Biopsy of Human Tumors

- a resource for Precision Medicine *

103 related articles for article (PubMed ID: 15228186)

  • 61. Long-term impact of delay in assessment of patients with early arthritis.
    van der Linden MP; le Cessie S; Raza K; van der Woude D; Knevel R; Huizinga TW; van der Helm-van Mil AH
    Arthritis Rheum; 2010 Dec; 62(12):3537-46. PubMed ID: 20722031
    [TBL] [Abstract][Full Text] [Related]  

  • 62. Upregulated baseline plasma CCL19 and CCR7 cell-surface expression on monocytes in early rheumatoid arthritis normalized during treatment and CCL19 correlated with radiographic progression.
    Ellingsen T; Hansen I; Thorsen J; Møller BK; Tarp U; Lottenburger T; Andersen LS; Skjødt H; Pedersen JK; Lauridsen UB; Svendsen A; Lindegaard H; Jacobsen S; Østergaard M; Vestergaard A; Jurik AG; Junker P; Christensen AF; Hetland ML; Hørslev-Petersen K; Stengaard-Pedersen K
    Scand J Rheumatol; 2014; 43(2):91-100. PubMed ID: 23980529
    [TBL] [Abstract][Full Text] [Related]  

  • 63. Aiming at low disease activity in rheumatoid arthritis with initial combination therapy or initial monotherapy strategies: the BeSt study.
    Allaart CF; Goekoop-Ruiterman YP; de Vries-Bouwstra JK; Breedveld FC; Dijkmans BA;
    Clin Exp Rheumatol; 2006; 24(6 Suppl 43):S-77-82. PubMed ID: 17083767
    [TBL] [Abstract][Full Text] [Related]  

  • 64. Etanercept for the treatment of rheumatoid arthritis.
    Lethaby A; Lopez-Olivo MA; Maxwell L; Burls A; Tugwell P; Wells GA
    Cochrane Database Syst Rev; 2013 May; 2013(5):CD004525. PubMed ID: 23728649
    [TBL] [Abstract][Full Text] [Related]  

  • 65. Association of socioeconomic status with treatment delays, disease activity, joint damage, and disability in rheumatoid arthritis.
    Molina E; Del Rincon I; Restrepo JF; Battafarano DF; Escalante A
    Arthritis Care Res (Hoboken); 2015 Jul; 67(7):940-6. PubMed ID: 25581770
    [TBL] [Abstract][Full Text] [Related]  

  • 66. Targeted treatment with a combination of traditional DMARDs produces excellent clinical and radiographic long-term outcomes in early rheumatoid arthritis regardless of initial infliximab. The 5-year follow-up results of a randomised clinical trial, the NEO-RACo trial.
    Rantalaiho V; Kautiainen H; Korpela M; Hannonen P; Kaipiainen-Seppänen O; Möttönen T; Kauppi M; Karjalainen A; Laiho K; Laasonen L; Hakola M; Peltomaa R; Leirisalo-Repo M;
    Ann Rheum Dis; 2014 Nov; 73(11):1954-61. PubMed ID: 23908187
    [TBL] [Abstract][Full Text] [Related]  

  • 67. Contemporary use of disease-modifying drugs in the management of patients with early rheumatoid arthritis in Norway.
    Nikolaisen C; Kvien TK; Mikkelsen K; Kaufmann C; Rødevand E; Nossent JC
    Scand J Rheumatol; 2009; 38(4):240-5. PubMed ID: 19229766
    [TBL] [Abstract][Full Text] [Related]  

  • 68. Misclassification of disease activity when assessing individual patients with early rheumatoid arthritis using disease activity indices that do not include joints of feet.
    Bakker MF; Jacobs JW; Kruize AA; van der Veen MJ; van Booma-Frankfort C; Vreugdenhil SA; Bijlsma JW; Lafeber FP; Welsing PM
    Ann Rheum Dis; 2012 Jun; 71(6):830-5. PubMed ID: 22128075
    [TBL] [Abstract][Full Text] [Related]  

  • 69. Prevalence of and predictive factors for sustained disease-modifying antirheumatic drug-free remission in rheumatoid arthritis: results from two large early arthritis cohorts.
    van der Woude D; Young A; Jayakumar K; Mertens BJ; Toes RE; van der Heijde D; Huizinga TW; van der Helm-van Mil AH
    Arthritis Rheum; 2009 Aug; 60(8):2262-71. PubMed ID: 19644846
    [TBL] [Abstract][Full Text] [Related]  

  • 70. High anti-cyclic citrullinated peptide levels and an algorithm of four variables predict radiographic progression in patients with rheumatoid arthritis: results from a 10-year longitudinal study.
    Syversen SW; Gaarder PI; Goll GL; Ødegård S; Haavardsholm EA; Mowinckel P; van der Heijde D; Landewé R; Kvien TK
    Ann Rheum Dis; 2008 Feb; 67(2):212-7. PubMed ID: 17526555
    [TBL] [Abstract][Full Text] [Related]  

  • 71. The influence of age at disease onset on disease activity and disability: results from the Ontario Best Practices Research Initiative.
    Ruban TN; Jacob B; Pope JE; Keystone EC; Bombardier C; Kuriya B
    Clin Rheumatol; 2016 Mar; 35(3):759-63. PubMed ID: 26245721
    [TBL] [Abstract][Full Text] [Related]  

  • 72. The course of radiologic damage during the first six years of rheumatoid arthritis.
    Hulsmans HM; Jacobs JW; van der Heijde DM; van Albada-Kuipers GA; Schenk Y; Bijlsma JW
    Arthritis Rheum; 2000 Sep; 43(9):1927-40. PubMed ID: 11014342
    [TBL] [Abstract][Full Text] [Related]  

  • 73. Disease-modifying antirheumatic drug-free sustained remission in rheumatoid arthritis: an increasingly achievable outcome with subsidence of disease symptoms.
    Ajeganova S; van Steenbergen HW; van Nies JA; Burgers LE; Huizinga TW; van der Helm-van Mil AH
    Ann Rheum Dis; 2016 May; 75(5):867-73. PubMed ID: 25972519
    [TBL] [Abstract][Full Text] [Related]  

  • 74. Factors associated with the initiation of biologic disease-modifying antirheumatic drugs in Texas Medicaid patients with rheumatoid arthritis.
    Kim G; Barner JC; Rascati K; Richards K
    J Manag Care Spec Pharm; 2015 May; 21(5):401-7. PubMed ID: 25943001
    [TBL] [Abstract][Full Text] [Related]  

  • 75. Prognostic factors for radiographic damage in early rheumatoid arthritis: a multiparameter prospective study.
    Combe B; Dougados M; Goupille P; Cantagrel A; Eliaou JF; Sibilia J; Meyer O; Sany J; Daurès JP; Dubois A
    Arthritis Rheum; 2001 Aug; 44(8):1736-43. PubMed ID: 11508423
    [TBL] [Abstract][Full Text] [Related]  

  • 76. Clinical and radiographic outcome of a treat-to-target strategy using methotrexate and intra-articular glucocorticoids with or without adalimumab induction: a 2-year investigator-initiated, double-blinded, randomised, controlled trial (OPERA).
    Hørslev-Petersen K; Hetland ML; Ørnbjerg LM; Junker P; Pødenphant J; Ellingsen T; Ahlquist P; Lindegaard H; Linauskas A; Schlemmer A; Dam MY; Hansen I; Lottenburger T; Ammitzbøll CG; Jørgensen A; Krintel SB; Raun J; Johansen JS; Østergaard M; Stengaard-Pedersen K;
    Ann Rheum Dis; 2016 Sep; 75(9):1645-53. PubMed ID: 26489704
    [TBL] [Abstract][Full Text] [Related]  

  • 77. Rheumatoid arthritis seems to have DMARD treatment decision influenced by fibromyalgia.
    Chakr RMDS; Brenol C; Ranzolin A; Bernardes A; Dalosto AP; Ferrari G; Scalco S; Olszewski V; Kohem C; Monticielo O; Brenol JCT; Xavier RM
    Rev Bras Reumatol Engl Ed; 2017; 57(5):403-411. PubMed ID: 29037312
    [TBL] [Abstract][Full Text] [Related]  

  • 78. The effect of HLA-DRB1 genes, rheumatoid factor, and treatment on radiographic disease progression in rheumatoid arthritis over 6 years.
    Rau R; Herborn G; Zueger S; Fenner H
    J Rheumatol; 2000 Nov; 27(11):2566-75. PubMed ID: 11093435
    [TBL] [Abstract][Full Text] [Related]  

  • 79. Predictors of radiographic joint damage in patients with early rheumatoid arthritis.
    Jansen LM; van der Horst-Bruinsma IE; van Schaardenburg D; Bezemer PD; Dijkmans BA
    Ann Rheum Dis; 2001 Oct; 60(10):924-7. PubMed ID: 11557647
    [TBL] [Abstract][Full Text] [Related]  

  • 80. Clinical significance of high levels of soluble tumour necrosis factor-α receptor-2 produced by alternative splicing in rheumatoid arthritis: a longitudinal prospective cohort study.
    Cañete JD; Albaladejo C; Hernández MV; Laínez B; Pinto JA; Ramírez J; López-Armada MJ; Rodríguez-Cros JR; Engel P; Blanco FJ; Sanmartí R
    Rheumatology (Oxford); 2011 Apr; 50(4):721-8. PubMed ID: 21134963
    [TBL] [Abstract][Full Text] [Related]  

    [Previous]   [Next]    [New Search]
    of 6.